Anixa Biosciences (ANIX) Operating Expenses (2010 - 2026)
Anixa Biosciences' (ANIX) quarterly Operating Expenses came in at $2.6 million in Q2 2026, down 11.85% YoY from $3.0 million in Q2 2025, and down 7.96% on a QoQ basis from $2.9 million in Q4 2025.
Anixa Biosciences (ANIX) Operating Expenses (2010 - 2026) Analysis & Trends
Anixa Biosciences (ANIX) has 17 years of Operating Expenses data on file, last reported at $2.6 million in Q2 2026.
- Quarterly Operating Expenses fell 11.85% year-over-year to $2.6 million in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $11.0 million (down 16.6% YoY) and the FY2025 annual result came in at $11.7 million, down 15.4% from the prior year.
- Operating Expenses retreated to $2.6 million in Q2 2026, from $2.9 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $3.9 million in Q1 2022 to a low of $2.4 million in Q3 2025.
- A 5-year average of $3.1 million and a median of $3.1 million in 2023 frame the typical range for Operating Expenses.
- The widest YoY moves for Operating Expenses: up 47.27% in 2022, down 36.26% in 2022.
- Tracing ANIX's Operating Expenses over 5 years: stood at $3.6 million in 2022, then fell by 15.46% to $3.1 million in 2023, then gained by 3.67% to $3.2 million in 2024, then retreated by 9.07% to $2.9 million in 2025, then dropped by 7.96% to $2.6 million in 2026.
- The last three Operating Expenses figures came in at $2.6 million (Q2 2026), $2.9 million (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.57 Bn | 131.72 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 65.44 Bn | 60.25 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 60.06 Bn | 54.93 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.89 Bn | 28.58 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.11 Bn | 9.72 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 541.02 Mn |
| 10 | Anixa Biosciences | 125.64 Mn | 125.64 Mn | - | 2.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 2.65 Mn |
| Oct 31, 2025 | 2.88 Mn |
| Jul 31, 2025 | 2.44 Mn |
| Apr 30, 2025 | 3.00 Mn |
| Jan 31, 2025 | 3.39 Mn |
| Oct 31, 2024 | 3.16 Mn |
| Jul 31, 2024 | 3.59 Mn |
| Apr 30, 2024 | 3.47 Mn |
| Jan 31, 2024 | 3.61 Mn |
| Oct 31, 2023 | 3.05 Mn |
| Jul 31, 2023 | 2.84 Mn |
| Apr 30, 2023 | 2.77 Mn |
| Jan 31, 2023 | 2.56 Mn |
| Oct 31, 2022 | 3.61 Mn |
| Jul 31, 2022 | 2.80 Mn |
| Apr 30, 2022 | 3.59 Mn |
| Jan 31, 2022 | 3.88 Mn |
| Oct 31, 2021 | 4.08 Mn |
| Jul 31, 2021 | 4.39 Mn |
| Apr 30, 2021 | 2.44 Mn |